Robert Rosler

Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes†

Sean E. Doyle, Heidi Schreckhise, Kien Khuu-Duong et al. · Hepatology · 2006 · 343 citations

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

Anita Kulukian, Patrice Lee, Janelle Taylor et al. · Molecular Cancer Therapeutics · 2020 · 196 citations

A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo

Robert L. Mabry, Debra G. Gilbertson, Amanda Frank et al. · mAbs · 2010 · 55 citations · Full text